Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo covers the third quarter and first nine months ended September 30, 2003. The report details consolidated sales performance, product-specific growth, and geographical breakdowns. All financial figures are presented in millions of euros under French GAAP.
Key Financial Metrics
Sales Performance
- Q3 2003 Consolidated Sales: 2,037 million euros (+16.4% comparable; +9.2% reported).
- 9-Month 2003 Consolidated Sales: 5,940 million euros (+15.1% comparable; +7.1% reported).
- 9-Month Developed Sales: 7,631 million euros (+17.4% comparable).
Geographical Breakdown (9-Month 2003)
| Region | Sales (M EUR) | Change (Comparable) | Change (Reported) |
|---|---|---|---|
| Europe | 3,473 | +9.5% | +8.2% |
| United States | 1,413 | +34.6% | +14.0% |
| Rest of World | 1,054 | +12.0% | -4.0% |
| Total | 5,940 | +15.1% | +7.1% |
Top Product Performance (9-Month 2003)
- Plavix(R): 964 million euros (+36.0% comparable).
- Eloxatin(R): 600 million euros (+174.0% comparable).
- Stilnox(R)/Ambien(R): 995 million euros (+10.3% comparable; -6.4% reported due to currency).
- Aprovel(R): 506 million euros (+26.8% comparable).
Profitability and Cash Flow
The filing text does not provide specific values for net profit, operating income, cash flow, debt levels, or liquidity ratios. It only provides an Earnings Per Share (EPS) outlook.
Material Changes vs. Prior Period
- Currency Impact: Unfavorable currency fluctuations reduced reported growth by 7.5 percentage points over the nine-month period, primarily due to the weakening US dollar.
- US Sales Acceleration: US consolidated sales grew 34.6% on a comparable basis, driven largely by Eloxatin(R) (334 million euros) and Plavix(R).
- Ambien(R) Dynamics: US sales of Ambien(R) declined 6.3% on a comparable basis in Q3 due to high inventory build-up in Q3 2002 ahead of a price increase, despite a 13.9% rise in prescriptions.
- Portfolio Mix: The top 10 products accounted for 67.1% of consolidated sales in the first nine months, up from 60.1% in the prior year.
Guidance, Outlook, and Risks
Full-Year 2003 Outlook
Management confirmed the full-year forecasts upgraded on September 2, 2003:
- Sales Growth: Approximately 15% on a comparable basis.
- EPS Growth: Close to 20% (before exceptional items and goodwill amortization), assuming an average exchange rate of 1.10 USD to 1 EUR.
- Currency Sensitivity: EPS growth is sensitive to the dollar, with a 1% impact for every 3-cent movement in the exchange rate.
Risks and Contingencies
- Regulatory: FDA granted priority review for Eloxatin(R) for first-line treatment of metastatic colorectal cancer.
- Patent/Generics: Sales of Corotrope(R)/Primacor(R) have virtually disappeared due to generic introduction in the US.
- Forward-Looking Risks: Success of R&D programs, intellectual property protection, and healthcare reimbursement/pricing reforms in the US and France.
Investor Verification Checklist
- Verify the impact of the US dollar weakness on reported vs. comparable sales figures.
- Confirm the sustainability of Eloxatin(R) growth following FDA priority review.
- Monitor Ambien(R) inventory levels in the US to ensure they do not distort future sales comparisons.
- Review the specific terms of the alliance with Bristol-Myers Squibb regarding Plavix(R) and Aprovel(R) developed sales.
- Check for updates on the reimbursement environment in France and the US affecting pricing power.